Paper41008970
Elucidating Key Components and Mechanisms Underlying the Synergistic Anti-Type 2 Diabetes Effect of Morus alba L. and Siraitia grosvenorii Combination: An Integrated In Vitro Enzymology, Untargeted Metabolomics, and Network Pharmacology Approach.
He F and 9 others. Antioxidants (Basel), 2025. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Elucidating Key Components and Mechanisms Underlying the Synergistic Anti-Type 2 Diabetes Effect of Morus alba L. and Siraitia grosvenorii Combination: An Integrated In Vitro Enzymology, Untargeted Metabolomics, and Network Pharmacology Approach. Papers, record 41008970. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41008970
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Elucidating Key Components and Mechanisms Underlying the Synergistic Anti-Type 2 Diabetes Effect of Morus alba L. and Siraitia grosvenorii Combination: An Integrated In Vitro Enzymology, Untargeted Metabolomics, and Network Pharmacology Approach.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32660357 | Kinetic analysis of inhibition of α-glucosidase by leaf powder from Morus australis and its component iminosugars. | Biosci Biotechnol Biochem | 2020 | https://conductscience.org/library/papers/32660357 | PubMed |
| 2 | 35887036 | Anti-Inflammatory Activity of Mulberry Leaf Flavonoids In Vitro and In Vivo. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35887036 | PubMed |
| 3 | 35656159 | Comparison of the Fungal Community, Chemical Composition, Antioxidant Activity, and Taste Characteristics of Fu Brick Tea in Different Regions of China. | Front Nutr | 2022 | https://conductscience.org/library/papers/35656159 | PubMed |
| 4 | 33084336 | A GPU-Accelerated Fast Multipole Method for GROMACS: Performance and Accuracy. | J Chem Theory Comput | 2020 | https://conductscience.org/library/papers/33084336 | PubMed |
| 5 | 31610280 | Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells. | Int J Pharm | 2019 | https://conductscience.org/library/papers/31610280 | PubMed |
| 6 | 33489086 | Should metformin remain the first-line therapy for treatment of type 2 diabetes? | Ther Adv Endocrinol Metab | 2021 | https://conductscience.org/library/papers/33489086 | PubMed |
| 7 | 38154388 | Apigenin analogs as α-glucosidase inhibitors with antidiabetic activity. | Bioorg Chem | 2024 | https://conductscience.org/library/papers/38154388 | PubMed |
| 8 | 34895945 | Network pharmacology: curing causal mechanisms instead of treating symptoms. | Trends Pharmacol Sci | 2022 | https://conductscience.org/library/papers/34895945 | PubMed |
| 9 | 23614898 | Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. | Cancer Discov | 2013 | https://conductscience.org/library/papers/23614898 | PubMed |
| 10 | 38914383 | Activation and modulation of the AGEs-RAGE axis: Implications for inflammatory pathologies and therapeutic interventions - A review. | Pharmacol Res | 2024 | https://conductscience.org/library/papers/38914383 | PubMed |
| 11 | 30551359 | In vitro and in vivo evidence that quercetin protects against diabetes and its complications: A systematic review of the literature. | Biomed Pharmacother | 2019 | https://conductscience.org/library/papers/30551359 | PubMed |
| 12 | 22766319 | Novel links between HIFs, type 2 diabetes, and metabolic syndrome. | Trends Endocrinol Metab | 2012 | https://conductscience.org/library/papers/22766319 | PubMed |
| 13 | 28124574 | Curcumin regulates insulin pathways and glucose metabolism in the brains of APPswe/PS1dE9 mice. | Int J Immunopathol Pharmacol | 2017 | https://conductscience.org/library/papers/28124574 | PubMed |
| 14 | 39382753 | Clinical research progress on β-cell dysfunction in T2DM development in the Chinese population. | Rev Endocr Metab Disord | 2025 | https://conductscience.org/library/papers/39382753 | PubMed |
| 15 | 31942844 | 1-Deoxynojirimycin and its Derivatives: A Mini Review of the Literature. | Curr Med Chem | 2021 | https://conductscience.org/library/papers/31942844 | PubMed |
| 16 | 35151421 | Mechanisms underlying the pathophysiology of type 2 diabetes: From risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia. | Mutat Res Genet Toxicol Environ Mutagen | 2022 | https://conductscience.org/library/papers/35151421 | PubMed |
| 17 | 31908653 | IRS1/PI3K/AKT pathway signal involved in the regulation of glycolipid metabolic abnormalities by Mulberry (Morus alba L.) leaf extracts in 3T3-L1 adipocytes. | Chin Med | 2020 | https://conductscience.org/library/papers/31908653 | PubMed |
| 18 | 26062160 | Umbelliferone Improves an Impaired Glucose and Lipid Metabolism in High-Fat Diet/Streptozotocin-Induced Type 2 Diabetic Rats. | Phytother Res | 2015 | https://conductscience.org/library/papers/26062160 | PubMed |
| 19 | 36858276 | Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. | J Ethnopharmacol | 2023 | https://conductscience.org/library/papers/36858276 | PubMed |
| 20 | 24825096 | Caffeic and chlorogenic acids inhibit key enzymes linked to type 2 diabetes (in vitro): a comparative study. | J Basic Clin Physiol Pharmacol | 2015 | https://conductscience.org/library/papers/24825096 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42739092 | A Combination of Psidium guajava and Seriphium plumosum Modulates Glucose Metabolism and Reduces Hepatic GLUT2 Expression Through Additive-to-Synergistic Interactions. | Nutrients | 2026 | https://conductscience.org/library/papers/42739092 | PubMed |
| 42395743 | Theacrine-rich Jianghua Kucha black tea alleviates depression via remodeling systemic tryptophan metabolism and targeting TPH1: insights from metabolomics and molecular simulation. | RSC Adv | 2026 | https://conductscience.org/library/papers/42395743 | PubMed |
| 41952890 | Systemic effects of type 2 diabetes therapies: an integrated perspective on the cardio-renal- cerebral-metabolic axis. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/41952890 | PubMed |
| 41952002 | Computational framework to quantify synergistic ligand activity in insulin secretion and resistance pathways in type 2 diabetes. | J Comput Aided Mol Des | 2026 | https://conductscience.org/library/papers/41952002 | PubMed |
| 41596150 | Potential Health Benefits of Dietary Antioxidants. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/41596150 | PubMed |
| 41596103 | Dietary Starch-Extract Complexes from Cerrado Fruits Modulate Oxidative Stress in Mononuclear Cells from Normoglycemic and Diabetic Individuals. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/41596103 | PubMed |
| 41149577 | A Sulfated Polysaccharide from the Green Alga Caulerpa taxifolia: Characteristics of Its Structure and Anti-Diabetic Activity. | Mar Drugs | 2025 | https://conductscience.org/library/papers/41149577 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41008970
GET https://conductscience.org/api/papers/v1/41008970/references?page=2